<DOC>
	<DOCNO>NCT03083171</DOCNO>
	<brief_summary>In randomize , double-blind , placebo-controlled study , either single dose Adrecizumab ( 0.5 , 2.0 8.0 mg/kg ) placebo administrate 24 healthy male volunteer experimental endotoxemia .</brief_summary>
	<brief_title>Adrecizumab-LPS Study</brief_title>
	<detailed_description>Adrenomedullin ( ADM ) natural occur 52 amino acid peptide mainly express endothelial smooth muscle cell . ADM plasma level increase patient sepsis relate severity disease . ADM key regulator vasotonus endothelial integrity sepsis . Adrecizumab antibody N-terminus ADM partially inhibit bioactivity ADM. Several septic animal study show administration Adrecizumab lead stabilization hemodynamics mouse pig , improve renal function , reduce catecholamine demand , improved fluid balance improve survival . The administration Adrecizumab rodent , non-human primate recently human , tolerate well . The experimental human endotoxemia model , healthy male volunteer receive low dose lipopolysaccharide ( LPS ) derive Escherichia coli , widely use study effect systemic inflammation human vivo consider safe highly reproducible method activate innate immune system . Furthermore , previous data show experimental human endotoxemia result increase plasma ADM level . In study , investigator wish assess safety , tolerability pharmacokinetics/-dynamics Adrecizumab inflammatory condition healthy volunteer .</detailed_description>
	<criteria>1 . Written inform consent participate trial prior studymandated procedure . 2 . Male subject age 18 35 year inclusive . 3 . Subjects agree use reliable way contraception partner study entry 3 month study drug administration . 4 . BMI 18 30 kg/m² , low limit body weight 50 kg upper limit 100 kg . 5 . Healthy determine medical history , physical examination , vital sign , 12lead electrocardiogram , clinical laboratory parameter . 1 . Unwillingness abstain medication , include recreational drug vitamin supplement course study within 7 day prior treatment day . 2 . Unwillingness abstain smoking , alcohol , within 1 day prior treatment day 1 day treatment day . 3 . Previous participation trial LPS administer . 4 . Surgery trauma significant blood loss blood donation within 3 month prior treatment day . 5 . History , sign symptoms cardiovascular disease , particular : History frequent vasovagal collapse orthostatic hypotension Resting pulse rate ≤45 ≥100 beats/min Hypertension ( RR systolic &gt; 160 RR diastolic &gt; 90 mmHg ) Hypotension ( RR systolic &lt; 100 RR diastolic &lt; 50 mmHg ) Conduction abnormalities ECG consist 1st degree atrioventricular block complex bundle branch block Any chronic cardiac arrhythmia ( except PAC 's , PVC 's ) 6 . Renal impairment : plasma creatinine &gt; 120 μmol/L 7 . Liver function test ( alkaline phosphatase , AST , ALT and/or γGT ) 2x upper limit normal . 8 . History asthma 9 . Atopic constitution 10 . CRP 2x upper limit normal , clinically significant acute illness , include infection , within 2 week prior treatment day . 11 . Treatment investigational drug participation clinical trial within 30 day prior treatment day . 12 . Known suspect able comply trial protocol . 13 . Known hypersensitivity excipients drug formulation use . 14 . Inability personally provide write informed consent ( e.g . linguistic mental reason ) and/or take part study .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Adrecizumab</keyword>
	<keyword>Adrenomedullin</keyword>
	<keyword>Healthy volunteer</keyword>
	<keyword>LPS</keyword>
	<keyword>Monoclonal recombinant antibody</keyword>
</DOC>